These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12400987)

  • 21. Interleukin-2 in outpatients with renal cell carcinoma: SCAPP1 trial.
    Tourani JM; Grise P; Lucas V; Mayeur D; Dufour B; Di Palma M; Boaziz C; Pavlovitch JM; Pujade-Lauraine E; Larregain D; Untereiner M
    Cancer Biother Radiopharm; 1996 Oct; 11(5):297-300. PubMed ID: 10851507
    [No Abstract]   [Full Text] [Related]  

  • 22. Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
    McDermott DF
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):716s-720s. PubMed ID: 17255299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrence of pemphigus vulgaris associated with interleukin 2 therapy.
    Prussick R; Plott RT; Stanley JR
    Arch Dermatol; 1994 Jul; 130(7):890-3. PubMed ID: 7794299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy.
    Gay HA; Cavalieri R; Allison RR; Finley J; Quan WD
    Dermatol Online J; 2007 Oct; 13(4):6. PubMed ID: 18319003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer.
    Heinzer H; Huland E; Huland H
    World J Urol; 2001 Apr; 19(2):111-9. PubMed ID: 11374313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metastatic type-2 papillary renal cell carcinoma responded to interleukin-2 therapy: case report.
    Kosaka T; Mikami S; Miyajima A; Oya M
    Clin Exp Nephrol; 2008 Apr; 12(2):155-158. PubMed ID: 18209950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stimulation of IL-18 secretion by IL-2 in patients with advanced cancer.
    Lissoni P; Rovelli F; Vellani D; Malugani F; Bucovec R; Chapovalenko L; Fumagalli E; Gardani G
    Int J Biol Markers; 2001; 16(2):146-7. PubMed ID: 11471899
    [No Abstract]   [Full Text] [Related]  

  • 28. Epidural metastasis in nasopharyngeal carcinoma.
    Bagatzounis A; Erakleous E; Michaelides I
    Strahlenther Onkol; 2003 Feb; 179(2):123-8. PubMed ID: 12590324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Advice from Public Health Council concerning administration of interleukin-2 in patients with renal cell tumor].
    van Maanen L
    Oncologica; 1994 May; 11(2):31-2. PubMed ID: 8025832
    [No Abstract]   [Full Text] [Related]  

  • 30. Prognostic implications of polymorphisms and interleukin-2 therapy for renal cell carcinoma.
    Gardner TA; Logan T
    J Urol; 2009 Aug; 182(2):425-6. PubMed ID: 19524946
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunotherapy in metastatic renal cell carcinoma.
    Rohrmann K; Staehler M; Haseke N; Bachmann A; Stief CG; Siebels M
    World J Urol; 2005 Jul; 23(3):196-201. PubMed ID: 15806434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-2 chronotherapy for metastatic renal cell carcinoma: Results of a phase I-II study.
    Re GL; Santeufemia DA; Re FL; Bortolus R; Doretto P; Marus W; Buttazzi L; Lenardon O; Falda A; Piazza R; Sulfaro S
    Cytokine; 2020 Apr; 128():154984. PubMed ID: 31972343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinoma.
    Simonelli C; Talamini R; Bearz A; Berretta M; Spazzapan S; Monini P; Sgadari C; Sartor I; Ensoli B; Tirelli U
    Ann Oncol; 2006 Aug; 17(8):1335-6. PubMed ID: 16569648
    [No Abstract]   [Full Text] [Related]  

  • 34. [Interferon-based cytokine therapy for advanced renal cell carcinoma].
    Takayama T; Kai F; Sugiyama T; Furuse H; Mugiya S; Ozono S
    Hinyokika Kiyo; 2005 Aug; 51(8):499-502. PubMed ID: 16164263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytokine therapy for metastatic renal cell carcinoma.
    Bukowski RM
    Semin Urol Oncol; 2001 May; 19(2):148-54. PubMed ID: 11354535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-2 in the treatment of renal cell carcinoma and malignant melanoma.
    Eklund JW; Kuzel TM
    Cancer Treat Res; 2005; 126():263-87. PubMed ID: 16209070
    [No Abstract]   [Full Text] [Related]  

  • 38. Interleukin 2 in cancer therapy.
    Antony GK; Dudek AZ
    Curr Med Chem; 2010; 17(29):3297-302. PubMed ID: 20712575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study.
    Walther MM; Lyne JC; Libutti SK; Linehan WM
    Urology; 1999 Mar; 53(3):496-501. PubMed ID: 10096373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metastatic renal cell carcinoma: systemic treatment.
    Abi-Aad AS; deKernion JB
    Acta Urol Belg; 1996 May; 64(2):3-8. PubMed ID: 8701805
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.